Breaking News Headlines Today

News from dermatologytimes.com

Ground News rates dermatologytimes.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

We’ve assigned a rating of Unknown factuality to dermatologytimes.com. You can read more about how we’ve determined dermatologytimes.com’s credibility and reliability as a news source here: https://ground.news/rating-system.

Information about dermatologytimes.com

Where is dermatologytimes.com located?dermatologytimes.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top dermatologytimes.com News

Rallies

Alumis Stock Nearly Doubles on Psoriasis Drug Trial, FDA Plans

75% Center coverage: 4 sources

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.See the Story

Obesity

Lilly’s Zepbound Plus Taltz Boosts Arthritis Relief, Weight Loss in Late-Stage Trial

100% Center coverage: 3 sources

Data show that a combination treatment, including the therapy Taltz, was more effective than older therapy alone.See the Story

United States · United States

MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars - MoonLake (NASDAQ:MLTX)

100% Center coverage: 1 sources

MoonLake says FDA may allow approval filing for its HS drug Sonelokimab without new trials after strong study results, keeping its 2026 submission plans on track.See the Story

News from dermatologytimes.com

News from dermatologytimes.com

Information about dermatologytimes.com

Media Bias Ratings

Factuality

Ownership

Top dermatologytimes.com News

Alumis Stock Nearly Doubles on Psoriasis Drug Trial, FDA Plans

Lilly’s Zepbound Plus Taltz Boosts Arthritis Relief, Weight Loss in Late-Stage Trial

MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars - MoonLake (NASDAQ:MLTX)

Similar News Topics

Topics Most Covered by dermatologytimes.com

Sources Covering Similar Topics

Breaking News Topics Related to dermatologytimes.com